

(ONOV)

A Nevada Corporation

Annual Report

For The Year Ending December 31, 2015

1) The exact name of the issuer and its predecessor (if any)

BioNovelus, Inc.

Firstin Wireless Technology, Inc. (until May 15, 2015)

Formerly Passionate Pet, Inc. (until January 31, 2013)

2) The address of the issuer's principal executive offices

15560 N. Frank Lloyd Wright Blvd.
Suite B4-421
Scottsdale, AZ 85260
TEL: 602-881-0438
Website: http://bionovelus.com

3) Security Information

Trading Symbol: ONOV
Exact title and class of securities outstanding: Common CUSIP: 09073X100
Par or Stated Value: $0.001
Total shares authorized: 500,000,000 as of: September 30, 2015
Total shares outstanding: 83,267,969 as of: December 31, 2015

Exact title and class of securities outstanding: Preferred
CUSIP: None
Par or Stated Value: $0.001
Total shares authorized: 10,000,000 as of: June 30, 2015
Total shares outstanding: 10,000,000 as of: December 31, 2015

Transfer Agent VStock Transfer LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516
Phone: 212-828-8436 Toll-Free: 855-VSTOCK Fax: 646-536-3179
info@vstocktransfer.com

VStock Transfer LLC is registered with the Securities and Exchange Commission as a transfer agent pursuant to Section 17A(c) of the Exchange Act.

No restrictions on the transfer of security.

No trading suspension orders issued by the SEC in the past 12 months.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either

currently anticipated or that occurred within the past 12 months: On January 22, 2013 the Company filed a Certificate of Amendment to Articles of Incorporation with the state of Nevada changing its name from Passionate Pet, Inc. to Firstin Wireless Technology, Inc. At the same time outstanding shares of common stock of the Company were reversed on a 1 for 250 basis which was effected on January 31, 2013. On March 30, 2015 the Company filed a Certificate of Amendment to Articles of Incorporation with the state of Nevada changing its name from Firstin Wireless Technology, Inc. to BioNovelus, Inc. At the same time outstanding shares of common stock of the Company were reversed on a 1 for 750 basis.

Issuance History

During the year 2013, the Company issued common shares as described below:

- 54,417,656 shares of common stock pursuant to the exchange agreement with Firstin Wireless Technology, Inc.
- 32, 500,000 common shares for elimination of debt to noteholder

During the year 2014, the Company issued common shares as described below:

- Issued 12,187,500 common shares for elimination of debt to noteholder
- Issued 10,000,000 preferred shares for elimination of debt to noteholder

During the year 2015, the Company issued common shares as described below:

- 70,000,000 shares of common stock pursuant to the agreement with BioNovelus, Inc.

All shares issued contained a restricted legend stating that the shares have not been registered under the Securities Act and this legend further set forth the restrictions on transferability and sale of the shares under the Securities Act.

4) Financial Statements

The Issuer is providing the following financial statements for the quarter ending September 30, 2015 and financial notes, both of which were filed with OTC Markets on October 15, 2015. These unaudited financial statements and financial notes are incorporated by reference herein.

Firstin Wireless, Inc. ended its Fiscal Year each September, 30.
BioNovelus, Inc. has elected to end its Fiscal Year December 31, 2015.

On December 7 2015
BioNovelus September 2015 Financial statements where amended for the correction of errors.
All research and development costs are normally expensed as incurred.
Since there was a reverse acquisition/merger, those rules change per GAAP, or generally accepted accounting principles.
Since the one company is essentially buying the developed product, the idea of intellectual property comes about.
This property needs to be valued at either historical cost of the R&D or the fair market value, whichever is more

readily available.
And in this case since the stock is being issued for the product, the cost of the stock (which is $0.01 per share) becomes the fair market value based on the number of shares.
To calculate the fair market value, the number of shares was multiplied by $0.01 to come up with the fair market value.
This method is also the way the SEC values similar property, so we need to be in accordance with both GAAP and the SEC.

5) Describe the Issuer's Business, Products and Services

The Company operated a retail pet and supply store in Irvine, California which ran its operations and also sold retail premium pet food, supplies and service to the general public, through a wholly owned subsidiary until the lessor of the building evicted the Company on January 16, 2012. The eviction caused the discontinuation of operations in that location. The Company decided to dispose of this business unit primarily because it has incurred significant operating losses in each of the last two years as the operations could not generate enough revenues to satisfy the significant rent and occupancy costs in the last two years. On July 31, 2012, the former CEO, John Dunn entered into an agreement with the Company to sell 100% of his interest in the Company and assume the net assets and liabilities of the wholly owned subsidiary. As a result, the subsidiary together with its assets and liabilities were wholly owned by Mr. Dunn.

On January 23, 2013, the Company entered into a Share Exchange Agreement with the Firstin Wireless Technology, Inc., a corporation formed under the laws of Canada (Firstin Canada), and the shareholders of Firstin Canada. Under the terms of this agreement, Firstin Canada will become the wholly owned subsidiary of the Company. On April 22, 2015, the Company entered into an Amalgamation Agreement with BioNovelus, Inc., an Arizona corporation. The new company, BioNovelus Inc. is a Nevada corporation.

The following business description and discussion regarding products relates to the operations of BioNovelus, Inc.

A. Description of the issuer's business operations

BioNovelus is a Clean Tech company whose vision is to answer critical environmental problems and to replace harmful chemicals with eco-friendly and profitable technologies in respect to our planet. Its mission is to offer proprietary disruptive green technologies that are innovative, cost-effective solutions for BioNovelus' customers, and partners, and benefit the shareholders and the planet at large.

There is an urgent need to keep ahead of both current and future pathogens, viruses and bacteria as well their resistant superbugs, and invasive species. Current products, many of which are toxic, while effective against many of these dangerous microbes, are corrosive, unstable, dangerous for transportation and for the environment, and cannot prevent re-infection. At BioNovelus, we passionately believe that "in this 21st Century it is time for harmful toxic chemicals to finally be replaced by new generations of eco-friendly, effective, and economical solutions to treat our water and our food."

B. The Company was incorporated in the State of Arizona on September 10, 2010.

C. The Issuer's primary SIC Code is 7389.

D. The Issuer's fiscal year end date is December 31th.

E. The Company's principal products or services, and their markets:

During this last Quarter, BioNovelus focused on testing its biocide on multiple applications. One of them is 'coffee rust control'.

Coffee is worth over $100 billion worldwide. That puts it ahead of commodities like natural gas, gold, brent oil, sugar and corn. Coffee is grown in over 50 countries in Asia, Africa, South America, Central America and the Caribbean. And 67 percent of the world's coffee is grown in the Americas alone.

Hemileia vastatrix, or coffee rust, causes some damage in any year but can be devastating when conditions are especially favorable for its rapid growth. Coffee rust has increased in 2015 due to climate change. The economic impact is over 1.4 billion dollars per year, along with over 500,000 jobs lost in Central America, and an increase of illegal immigration to the USA.

After the successful pilot test in Ivory Coast, followed by positive lab tests in Canada, BioNovelus is looking for partners and distributors in Costa Rica and Mexico to conduct more on site pilot testing to achieve regulatory approval to sell our product by the end of 2015 in these countries.

At the same time, BioNovelus is conducting other trials for applications in the biocide market that will be presented in the next Quarter.

Market

"Valued at 1.8 billion dollars in 2013, the global market for biopesticides is expected to reach $4.36 billion dollars by 2019, growing at a CAGR of 16.0% from 2014 to 2019. With these data and our positive lab and field results, we are very pleased to enter the market of biopesticides; our first product is designed as a biodegradable, eco-friendly alternative to toxic fungicides." says BioNovelus President Jean Ekobo. "Regulations for pesticides are becoming more rigorous, which will increase the demand for organic products."

The Biocide space was $7.2 billion in 2010, and is expected to reach $9.4 billion in 2016 at a CAGR of 4.3%. BionoPLUS, a biocide and fungicide, is a fast acting disinfectant. This biodegradable product is non-toxic, resistant to high temperatures, flocculent, and non-corrosive. This formula has been tested to also be a proven solution to fight certain invasive species. BionoPLUS available markets for commercialization are Water Treatment; Municipal Waste Treatment; Hydro-electric industry; Aquaculture, and Agricultural Treatment.

The Company is headquartered at 15560 N. Frank Lloyd Wright Blvd, Suite B4-421, Scottsdale AZ 85260. No rental agreement at this location, Home office.

6) Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons.

Name	Position	Share Ownership
Jean Ekobo	President, CEO, Chairman	36,050,000 (51%)
Nathalie Ekobo	Director of Marketing	21,000,000 (30%)

Joss Francheterre	Director	3,850,000 (5%)
Genesis Partners, LLC	Control Person	10,000,000 preferred
Richard Hess	Secretary	700,000 (<1%)
Marvin Clark	Director & Treasurer	N/A
Frederick F. Taylor	Director & General Counsel	N/A
Scott Yenglin	SVP	1,750,000 (2.5%)

B. Legal/Disciplinary History.

None of the foregoing persons mentioned in Item 8, Paragraph A hereinabove have, in the last five years, been the subject of: (1) a conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding a traffic violation and other minor offenses; (2) The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities or banking activities; (3) A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities & Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed; (4) The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Beneficial Shareholders.

	Name	**Amount**	**Percent**
Common Stock	Jean Ekobo 15560 N. Frank Lloyd Wright Blvd Suite B4-421 Scottsdale AZ 85260	36,050,000	51%
Common Stock	Nathalie Ekobo 15560 N. Frank Lloyd Wright Blvd Suite B4-421 Scottsdale AZ 85260	21,000,000	30%
Common Stock	Joss Francheterre 15560 N. Frank Lloyd Wright Blvd Suite B4-421, Scottsdale AZ 85260	3,850,000	5%

7) Third Party Providers

Legal Counsel
Frederick F. Taylor
5030 E. Sunrise Dr
Phoenix AZ 85044
TEL: (480) 626-0170

Accounting
Moffitt & Company, P.C.
Paradise Valley Office Park III
11811 N. Tatum Blvd, Suite 2600
Phoenix, AZ85028
TEL. : (480) 951-1416

8) Issuer Certification

I, Jean Ekobo, certify that:

1. I have reviewed this Annual Report of BioNovelus, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: February 25, 2015

JEAN EKOBO

Jean Ekobo
President